These findings suggest that lowering Lp(a) levels and/or blocking the specific pathways by which Lp(a) promotes CAVD could lead to therapies that slow the progression of CAVD. Here, LPA is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.